Show simple item record

dc.contributor.authorGoes, Adriely
dc.contributor.authorFuhrmann, Gregor
dc.date.accessioned2020-06-24T13:55:26Z
dc.date.available2020-06-24T13:55:26Z
dc.date.issued2018-03-29
dc.identifier.citationACS Infect Dis. 2018;4(6):881-892. doi:10.1021/acsinfecdis.8b00030.en_US
dc.identifier.pmid29553240
dc.identifier.doi10.1021/acsinfecdis.8b00030
dc.identifier.urihttp://hdl.handle.net/10033/622311
dc.description.abstractBiogenic and biomimetic therapeutics are a relatively new class of systems that are of physiological origin and/or take advantage of natural pathways or aim at mimicking these to improve selective interaction with target tissue. The number of biogenic and bioengineered avenues for drug therapy and diagnostics has multiplied over the past years for many applications, indicating the high expectations associated with this biological route. Nevertheless, the use of "bio"-related approaches for treating or diagnosing infectious diseases is still rare. Given that infectious diseases, in particular bacterial resistances, are seriously on the rise, there is an urgent need to take advantage of biogenic and bioengineered systems to target these challenges. In this manuscript, we first give a definition of the various "bio" terms, including biogenic, biomimetic, bioinspired, and bioengineered and we highlight them using tangible applications in the field of infectious diseases. Our examples cover cell-derived systems, including bioengineered bacteria, virus-like particles, and different cell-mimetics. Moreover, we discuss natural and bioengineered particles such as extracellular vesicles from mammalian and bacterial sources and liposomes. A concluding section outlines the potential for biomaterial-related avenues to overcome challenges associated with difficult-to-treat infections. We critically discuss benefits and risks for these applications and give an outlook on the future of biogenic engineering.en_US
dc.language.isoenen_US
dc.publisherAmerican Chemical Societyen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectbiogenic drug deliveryen_US
dc.subjectbioinspired delivery systemsen_US
dc.subjectbiomimeticsen_US
dc.subjectcell-mimeticsen_US
dc.subjectextracellular vesiclesen_US
dc.subjectnanoantibioticsen_US
dc.subjectouter membrane vesiclesen_US
dc.subjectvirus-like particlesen_US
dc.titleBiogenic and Biomimetic Carriers as Versatile Transporters To Treat Infections.en_US
dc.typeReviewen_US
dc.typeOtheren_US
dc.identifier.eissn2373-8227
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalACS infectious diseasesen_US
dc.source.volume4
dc.source.issue6
dc.source.beginpage881
dc.source.endpage892
refterms.dateFOA2020-06-24T13:55:27Z
dc.source.journaltitleACS infectious diseases
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Goes and Fuhrmann.pdf
Size:
4.366Mb
Format:
PDF
Description:
submitted manuscript

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International